Alnylam grants Quark InterfeRx license to develop RNAi therapeutics

By Lisa Kerner

Charlotte, N.C., Sept. 26 - Alnylam Pharmaceuticals, Inc. granted Quark Biotech, Inc. InterfeRx licenses to discover, develop and commercialize RNAi therapeutics targeting the p53 and RTP801 genes.

The Cambridge, Mass., biopharmaceutical company has granted six InterfeRx licenses to date, and 12 licenses in total for therapeutic RNAi applications, according to officials.

While detailed financial terms were not disclosed, upfront, annual and milestone payments, as well as royalties on product sales, are covered by the licensing agreements.

Quark will also no longer oppose the Kreutzer-Limmer patent series related to certain siRNAs currently granted in Europe. The Fremont, Calif., biopharmaceutical company's RNAi therapeutic targeting p53 is being developed to reduce tubular damage and preserve kidney function.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.